Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Remyelination

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Remyelination. Displaying page 1 of 1.
    EudraCT Number: 2006-006465-16 Sponsor Protocol Number: rhGH in MS Start Date*: Information not available in EudraCT
    Sponsor Name:University of Leipzig
    Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003475-11 Sponsor Protocol Number: UCL/11/0083 Start Date*: 2011-11-15
    Sponsor Name:University College London (UCL)
    Full Title: A phase II double-blind, randomised, placebo-controlled trial of neuroprotection with phenytoin in acute optic neuritis
    Medical condition: Acute demyelinating optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003145-99 Sponsor Protocol Number: CCMROne Start Date*: 2015-03-19
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised placebo-controlled study of the safety and tolerability of a retinoid-X receptor agonist's ability to promote remyelination in people with relapsing-remitting multiple sclerosis alread...
    Medical condition: Relapsing-remitting multiple sclerosis already on interferon-beta therapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003627-38 Sponsor Protocol Number: H3M116477 Start Date*: 2013-01-30
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects with Relapsing Remitting Multiple Sclerosis
    Medical condition: Relapsing Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) CZ (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001973-21 Sponsor Protocol Number: GNC-402 Start Date*: 2021-07-09
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A long-term extension of Study GNC-401 with temelimab in patients with Relapsing forms of Multiple Sclerosis (RMS) under treatment with rituximab
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003677-66 Sponsor Protocol Number: RESTORE Start Date*: 2022-02-14
    Sponsor Name:Amsterdam University Medical Center
    Full Title: Clemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis
    Medical condition: Multiple sclerosis (MS) Internuclear ophthalmoparesis (INO)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080865 Multiple sclerosis lesion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004935-18 Sponsor Protocol Number: GNC-004 Start Date*: 2017-04-12
    Sponsor Name:GeNeuro SA
    Full Title: A Long-Term International, Extension of Study GNC-003, with GNbAC1 in Patients with Relapsing Remitting Multiple Sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) HR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002357-35 Sponsor Protocol Number: CRO1959 Start Date*: 2012-10-23
    Sponsor Name:Imperial College London
    Full Title: Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-001756-35 Sponsor Protocol Number: 16/0163 Start Date*: 2019-06-21
    Sponsor Name:University of California, San Francisco
    Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Opti...
    Medical condition: acute optic neuritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10030942 Optic neuritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004822-15 Sponsor Protocol Number: GNC-401 Start Date*: 2020-05-18
    Sponsor Name:GeNeuro Innovation SAS
    Full Title: A Randomized, Double-Blind, Placebo Controlled Trial, Examining the Safety, Tolerability, Pharmacodynamic Effects and Pharmacokinetics of Temelimab Following Rituximab Treatment in Patients with Re...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004059-29 Sponsor Protocol Number: GNC-003 Start Date*: 2016-05-04
    Sponsor Name:GeNeuro SA
    Full Title: An international, double-blind, randomised, placebo-controlled phase IIb trial to assess the efficacy, safety, and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis
    Medical condition: Multiple Sclerosis (MS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed) ES (Completed) EE (Completed) PL (Completed) BG (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001227-31 Sponsor Protocol Number: NISCI Start Date*: 2019-06-19
    Sponsor Name:University Zurich, University Hospital Balgrist, Spinal Cord Injury Center
    Full Title: Antibodies against Nogo-A to enhance plasticity, regeneration and functional recovery after acute spinal cord injury
    Medical condition: spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022117 - Injury, poisoning and procedural complications 10041554 Spinal cord injury cervical PT
    20.1 10022117 - Injury, poisoning and procedural complications 10041552 Spinal cord injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2021-003577-63 Sponsor Protocol Number: DYNAMICS_Study Start Date*: 2022-04-06
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Effects of ozanimod on myelin dynamics and neurodegeneration in patients with relapsing-remitting multiple sclerosis: correlation with disease activity, cognition, fatigue, depression and quality o...
    Medical condition: Multiple sclerosis patients in relapse and remission form
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001224-22 Sponsor Protocol Number: 215MS202 Start Date*: 2017-12-28
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With Optional Open-Label Extension in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as ...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10067063 Progressive relapsing multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Prematurely Ended) CZ (Completed) HU (Prematurely Ended) BE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 18:46:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA